FibroBiologics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 16.49 million compared to USD 5.12 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to USD 0.18 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
11.76 USD | +4.07% | +23.01% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 367M | |
+7.21% | 111B | |
+10.15% | 106B | |
-12.25% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-9.21% | 16.81B | |
+38.12% | 12.54B | |
-24.98% | 8.09B |
- Stock Market
- Equities
- FBLG Stock
- News FibroBiologics, Inc.
- FibroBiologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023